RxSight (RXST) Enterprise Value (2021 - 2026)

RxSight (RXST) has reported Enterprise Value for 6 consecutive years, with -$203.8 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Enterprise Value fell 273.84% year-over-year to -$203.8 million; the trailing twelve-month figure through Jun 2026 stood at -$203.8 million (down 273.84% YoY), and the FY2025 full-year result was -$6.5 million, down 100.7% from the prior year.
• Enterprise Value slipped to -$203.8 million in Q2 2026 per RXST's latest filing, from -$163.3 million in the prior quarter.
• Across five years, Enterprise Value topped out at $1.9 billion in Q2 2024 and bottomed at -$203.8 million in Q2 2026.
• Historically, Enterprise Value has averaged $547.2 million across 5 years, with a median of $214.1 million in 2022.
• The sharpest annual moves came in 2023 and 2026: Enterprise Value jumped 665.48% in 2023, then tumbled 273.84% in 2026.
• Over 5 years, Enterprise Value stood at $158.4 million in 2022, then surged by 665.48% to $1.2 billion in 2023, then fell by 23.11% to $932.2 million in 2024, then tumbled by 100.7% to -$6.5 million in 2025, then slumped by 3017.58% to -$203.8 million in 2026.
• According to Business Quant data, Enterprise Value over the past three periods registered -$203.8 million, -$163.3 million, and -$6.5 million for Q2 2026, Q1 2026, and Q4 2025 respectively.